CA
ALLO icon

Continuum Advisory’s Allogene Therapeutics ALLO Stock Holding History

Continuum Advisory’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-510
Closed -$745 – 461
2025
Q1 		$745 Sell
510
-88
-15% -$166 ﹤0.01% 1546
2024
Q4 		$1.27K Sell
598
-14
-2% -$35 ﹤0.01% 1567
2024
Q3 		$1.51K Buy
612
+62
+11% +$165 ﹤0.01% 1529
2024
Q2 		$1.28K Hold
550
– – ﹤0.01% 1419
2024
Q1 		$1.57K Buy
+550
New +$2.29K ﹤0.01% 1363

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Continuum Advisory's ALLO Position: Q2 2025 in Review

Continuum Advisory sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 510 shares — an estimated $745 sold.

Continuum Advisory first reported a position in ALLO in Q1 2024 and held it in 5 quarters. The position peaked at $1.57K in Q1 2024. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

  • Continuum Advisory reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 510 Allogene Therapeutics shares in Q2 2025, an estimated $745.
  • Continuum Advisory first reported a position in Allogene Therapeutics in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Allogene Therapeutics position peaked at $1.57K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.